GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Quick Ratio

Moberg Pharma AB (Moberg Pharma AB) Quick Ratio : 3.04 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Moberg Pharma AB's quick ratio for the quarter that ended in Dec. 2023 was 3.04.

Moberg Pharma AB has a quick ratio of 3.04. It generally indicates good short-term financial strength.

The historical rank and industry rank for Moberg Pharma AB's Quick Ratio or its related term are showing as below:

MBGPF' s Quick Ratio Range Over the Past 10 Years
Min: 1.98   Med: 2.93   Max: 6.74
Current: 3.04

During the past 13 years, Moberg Pharma AB's highest Quick Ratio was 6.74. The lowest was 1.98. And the median was 2.93.

MBGPF's Quick Ratio is ranked better than
78.68% of 1074 companies
in the Drug Manufacturers industry
Industry Median: 1.34 vs MBGPF: 3.04

Moberg Pharma AB Quick Ratio Historical Data

The historical data trend for Moberg Pharma AB's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Quick Ratio Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.33 - 6.74 4.77 3.04

Moberg Pharma AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.77 4.58 2.60 4.28 3.04

Competitive Comparison of Moberg Pharma AB's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Quick Ratio falls into.



Moberg Pharma AB Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Moberg Pharma AB's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(6.775-0.694)/2.002
=3.04

Moberg Pharma AB's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(6.775-0.694)/2.002
=3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OTCPK:MBGPF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Moberg Pharma AB Quick Ratio Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (Moberg Pharma AB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.